MicroRNA expression profiling predicts clinical outcome of carboplatin/paclitaxel-based therapy in metastatic melanoma treated on the ECOG-ACRIN trial E2603

BACKGROUND: Carboplatin/paclitaxel (CP), with or without sorafenib, result in objective response rates of 18–20 % in unselected chemotherapy-naïve patients. Molecular predictors of survival and response to CP-based chemotherapy in metastatic melanoma (MM) are critical to improving the therapeutic in...

詳細記述

保存先:
書誌詳細
出版年:Clin Epigenetics
主要な著者: Villaruz, Liza C., Huang, Grace, Romkes, Marjorie, Kirkwood, John M., Buch, Shama C., Nukui, Tomoko, Flaherty, Keith T., Lee, Sandra J., Wilson, Melissa A., Nathanson, Katherine L., Benos, Panayiotis V., Tawbi, Hussein A.
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2015
主題:
Research
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4457092/
https://ncbi.nlm.nih.gov/pubmed/26052356
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13148-015-0092-2
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料